MIC
UTHR icon

Mubadala Investment Company’s United Therapeutics UTHR Stock Holding History

Mubadala Investment Company’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,029
Closed -$3.79M – 91
2025
Q3 		$3.79M Buy
+9,029
New +$3.04M 0.02% 31
2025
Q2 		– Sell
-6,404
Closed -$1.97M – 75
2025
Q1 		$1.97M Sell
6,404
-359
-5% -$123K 0.01% 50
2024
Q4 		$2.39M Buy
+6,763
New +$2.49M 0.01% 45

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Mubadala Investment Company's UTHR Position: Q4 2025 in Review

Mubadala Investment Company sold out of United Therapeutics (UTHR) in Q4 2025, closing a stake of 9,029 shares — an estimated $3.79M sold.

Mubadala Investment Company first reported a position in UTHR in Q4 2024 and held it in 3 quarters. The position peaked at $3.79M in Q3 2025. 838 funds tracked by Wall St. Rank hold UTHR as of Q4 2025.

  • Mubadala Investment Company reported no remaining United Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Mubadala Investment Company sold 9,029 United Therapeutics shares in Q4 2025, an estimated $3.79M.
  • Mubadala Investment Company first reported a position in United Therapeutics in Q4 2024 and held it in 3 quarters.
  • Mubadala Investment Company's United Therapeutics position peaked at $3.79M in Q3 2025.
  • 838 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2025.

Based on Mubadala Investment Company's 13F filing for Q4 2025, filed 17 Feb 2026.